Comparative Pharmacology
Head-to-head clinical analysis: IBU TAB 200 versus RIMADYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBU TAB 200 versus RIMADYL.
IBU-TAB 200 vs RIMADYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Selective cyclooxygenase-2 (COX-2) inhibitor, reducing prostaglandin synthesis involved in inflammation, pain, and fever.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
50-100 mg orally twice daily, or 100-200 mg rectally once daily (suppository).
None Documented
None Documented
2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect.
Terminal elimination half-life: 12–18 hours in dogs at recommended doses. Clinical context: Supports twice-daily dosing; longer half-life in some breeds may require dose adjustment.
Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%.
Primarily hepatic metabolism (oxidation, conjugation) with ~70% of metabolites excreted in urine and ~30% in feces via biliary elimination. Less than 5% excreted unchanged.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)